Format

Send to

Choose Destination
Clin Ther. 2014 Apr 1;36(4):560-6. doi: 10.1016/j.clinthera.2014.02.016. Epub 2014 Mar 14.

Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.

Author information

1
Mayo Clinic, Rochester, Minnesota.
2
Adelphi Values, Boston, Massachusetts. Electronic address: Stacie.hudgens@clinoutsolutions.com.
3
Mayo Clinic Cancer Center, Arizona.
4
Celgene Corporation, Summit, New Jersey.
5
The University of Texas MD Anderson Cancer Center, Houston, Texas.
6
Department of Internal Medicine, Ospedale di Circolo, Varese, Italy.
7
Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Spain.
8
Division of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, Florida.

Abstract

BACKGROUND:

Anemia is common in myeloproliferative neoplasm (MPN)-associated myelofibrosis. The Functional Assessment of Cancer Therapy (FACT) measurement system is a patient-reported outcomes instrument that documents symptoms of the diverse aspects of cancer treatment. One FACT version, FACT-Anemia (FACT-An), documents symptoms of anemia related to cancer. The FACT-An has been validated in diverse cancer populations, but not in MPN-associated myelofibrosis.

OBJECTIVE:

Our aim was to evaluate the relationship between anemia response to therapy with pomalidomide with or without corticosteroids and patient-reported outcomes using the FACT-An instrument.

METHODS:

Data were obtained from a Phase II, randomized, double-blind Bayesian pick-the-winner trial of prednisone and pomalidomide in patients with MPN-associated myelofibrosis and anemia (red blood cell-transfusion dependence). Details of the study, including definitions of anemia, anemia response, red blood cell-transfusion, red blood cell-transfusion dependence, and red blood cell-transfusion independence, are reported. Change in quality of life from randomization to the last cycle of therapy was evaluated using the FACT-An Physical Well Being, Functional Well Being, Trial Outcome Index, and Anemia domains. Clinically important differences were used to determine the smallest difference in scores that patients perceived as beneficial in the FACT-An domains of interest. Patients were classified as meeting clinically important differences for responsiveness if their change score from baseline was >1 SEM, indicating improvement.

RESULTS:

Eighty-five patients were studied. Thirty-one patients (37%) were classified as anemia responders by prospectively defined criteria. Across all FACT-An domains, anemia responders showed greater improvement in Physical Well Being, Functional Well Being, and Trial Outcome Index scores than did nonresponders. This improvement began at the second 28-day cycle of therapy and was sustained.

CONCLUSIONS:

We show a correlation between anemia response and improved quality of life measured by the FACT-An instrument in patients with MPN-associated myelofibrosis and anemia.

KEYWORDS:

FACT-An; MPN-associated myelofibrosis; anemia; cancer; clinical trial; fatigue; patient-reported outcome; prednisone; quality of life; responsiveness; validation study

PMID:
24636526
DOI:
10.1016/j.clinthera.2014.02.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center